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A B S T R A C T   
UDP-glucuronosyltransferases (UGTs), located in the endoplasmic reticulum of liver cells, are an important 
family of enzymes, responsible for the biotransformation of several endogenous and exogenous chemicals, 
including therapeutic drugs. However, the phenomenon of ‘latency’, i.e., full UGT activity revealed by disruption 
of the microsomal membrane, poses substantial challenges for predicting drug clearance based on in vitro glu-
curonidation assays. This work introduces a microfluidic reactor design comprising immobilized human liver 
microsomes to facilitate the study of UGT-mediated drug clearance under flow-through conditions. The per-
formance of the microreactor is characterized using glucuronidation of 8-hydroxyquinoline (via multiple UGTs) 
and zidovudine (via UGT2B7) as the model reactions. With the help of alamethicin and albumin effects, we show 
that conducting UGT metabolism assays under flow conditions facilitates in-depth mechanistic studies, which 
may also shed light on UGT latency.   
1. Introduction 
Enzymatic biotransformations via cytochrome P450 (CYP) and UDP- 
glucuronosyltransferase (UGT) systems are the major elimination 
pathways for most xenobiotic compounds, including therapeutic drugs 
(Williams et al., 2004). The CYP enzyme family catalyzes oxidoreductive 
reactions that introduce new functional moieties into the drug molecule, 
whereas the UGTs catalyze the addition of a glucuronic acid moiety into 
a drug, resulting in a water-soluble metabolite that is easily excreted 
from the body through bile or urine. While disturbances in CYP function 
are known to result in a myriad of clinically relevant drug-drug in-
teractions (DDI), glucuronide metabolites of therapeutic drugs are 
generally regarded as being inert and non-toxic. However, some drugs 
can also form unstable acyl glucuronides that possess cytotoxic prop-
erties (Regan et al., 2010) or act as irreversible inhibitors of CYPs, 
leading to interactions of clinical consequence associated particularly 
with CYP2C8 (Backman et al., 2009; Tornio et al., 2014). Excessive 
glucuronidation may also result in complete loss of drug efficacy. For 
example, raloxifene, a widely used drug in the treatment of osteoporosis, 
has a poor oral bioavailability (2%) due to its extensive presystemic 
glucuronidation (Hochner-Celnikier, 1999). On the other hand, 
morphine 6-glucuronide is an even more potent analgesic than the 
parent molecule itself (Klimas and Mikus, 2014). Consequently, pre-
clinical screening for UGT-mediated drug clearance (enzyme kinetics) 
and the interlinked DDIs is an essential part of the regulatory guidance 
for the pharmaceutical industry (EMA, 2012; FDA, 2020). On one hand, 
several in silico methods have been introduced to date in the effort to 
predict the metabolic fate of drugs. The construction of reliable 
computational models remains a challenge, however, and necessitates 
the use of experimental validation datasets (Kazmi et al., 2019). For this 
purpose, both in vitro human models and in vivo animal models are used. 
The species-specific differences, e.g., unique or disproportionate me-
tabolites produced in laboratory animals, possess yet another challenge 
to preclinical prediction of the metabolic fate of new drug candidates 
(Issa et al., 2017), leaving the in vitro assays on human-derived enzyme 
sources (i.e., cells and subcellular microsomal fractions) as the most 
feasible model for prediction of human drug metabolism in vitro. 
A significant challenge with human UGT assays in vitro is their 
limited capability to predict the intrinsic drug clearance (CLint) in vivo. 
As the UGT enzymes are membrane proteins embedded in the endo-
plasmic reticulum (ER) of liver cells, with the active site facing the 
luminal side (Tukey and Strassburg, 2000), the ER membrane forms a 
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physical barrier to the drug substrates. As a result, significant underes-
timation of drug glucuronidation is often associated with in vitro assays 
performed with hepatocytes or isolated microsomal preparations (Liu 
and Coughtrie, 2017; Soars, 2002). The exact mechanism of this phe-
nomenon, generally referred to as UGT latency, has not been explicitly 
elucidated. However, it has been reported that ER preparations, such as 
liver microsomes, show increased UGT activities if the microsomal 
membrane is physically or chemically disrupted, e.g., with the 
pore-forming agent alamethicin or surfactants, respectively (Liu and 
Coughtrie, 2017). Although intact hepatocyte cultures often better 
predict the in vivo clearance of UGT substrates (Engtrakul et al., 2005; 
Soars et al., 2002), the microsomal preparations are more feasible for 
mechanism-based drug metabolism studies and differentiating meta-
bolic interactions from other cellular processes, such as drug 
permeation. 
In this study, we developed a microfluidic reactor, incorporating 
immobilized human liver microsomes (HLM), for studying UGT meta-
bolism under flow-through conditions and shedding light on the mech-
anisms of UGT latency. Namely, conducting enzyme incubations under 
flow-through conditions allows time-resolved monitoring of the 
enzyme function, such as distinguishing between transient and steady- 
state reaction velocities, which facilitates mechanistic studies in ways 
not feasible for conventional (static) endpoint assays. In previous 
studies, a range of different protocols have been proposed for immobi-
lization of CYPs on both capillary-based and microfabricated reactors 
(Kiiski et al., 2019; Lee et al., 2013; Nicoli et al., 2008; Schejbal et al., 
2016), but prior research on UGT metabolism under flow-through con-
ditions is limited to only a handful of studies exploiting capillary-based 
approaches (Alebić-Kolbah and Wainer, 1993; Kim and Wainer, 2005; 
Sakai-Kato et al., 2004). In this study, we exploited modern micro-
fabrication techniques to realize microreactors featuring a precisely 
confined micropillar array as the solid support for the immobilization of 
HLM. Compared with packed-bed capillary reactors, the microfabricated 
pillar arrays enable better control over the total surface area for enzyme 
immobilization, and they are less prone to clogging compared with, for 
example, porous polymer monolith-based reactors (Munirathinam et al., 
2015). Microfabrication also enables much better multiplexing and 
integration possibilities than capillary systems (Suryawanshi et al., 
2018) and thus creation of microchannel networks that enable precise 
spatiotemporal control over drug concentrations. 
2. Material and methods 
2.1. Materials and reagents 
The monomers used for fabricating the microreactors, pentaery-
thritol tetrakis(3-mercaptopropionate) (‘tetrathiol’) (≥95.0%) and 
triallyl-1,3,5-triazine-2,4,6(1H,3H,5H)- trione (‘triallyl’) (≥98.0%), 
were purchased from Sigma-Aldrich (Saint Louis, MO) or Bruno Bock 
(Marschacht, Germany). The microfabricated masters were made using 
SU-8 100 (Micro Resist Technology, Berlin, Germany) and the poly 
(dimethylsiloxane) (PDMS) molds were prepared from Sylgard 184 
elastomer (Down Corning Corporation, Midland, MI). 
The reagents used for functionalization of the microreactor surface 
included biotin-PEG4-alkyne and ethylene glycol purchased from Sigma 
Aldrich (St. Louis, MO), Irgacure® TPO-L photoinitiator from BASF 
(Ludwigshafen, Germany), and streptavidin Alexa Fluor® 488 conjugate 
from Life Technologies (Eugene, OR). The lipids used for preparation of 
fusogenic liposomes were purchased from Avanti Polar Lipids 
(Alabaster, AL) and included 1,2-dioleoyl-3-trimethylammonium-pro-
pane (chloride salt) (DOTAP), 1,2-dioleoyl-sn-glycero-3-phosphoetha-
nolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N2 
(cap-biotinyl) (sodium salt) (biotin-cap-DOPE) and 1,2-dioleoyl-sn- 
glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) 
(ammonium salt) (lissamine rhodamine B-DOPE). 
The human liver microsomes (HLM, 20 donor pool, Corning® 
Gentest #452161, Lot 7331001) were purchased from Corning (Wies-
baden, Germany). The chemicals and reagents used in the enzyme in-
cubations included 8-hydroxyquinoline (8-HQ), 8-hydroxyquinoline- 
glucuronide, magnesium chloride hexahydrate, perchloric acid 
(HClO4), uridine 5’-diphosphoglucuronic acid trisodium salt (UDPGA), 
alamethicin, bovine serum albumin (BSA), Trizma® base and 
phosphate-buffered saline (PBS, pH 7.4), all purchased from Sigma 
Aldrich. Zidovudine and zidovudine glucuronide were from Toronto 
Research Chemicals (North York, ON). All chemicals used in the study 
were of analytical grade unless otherwise stated. Water was purified 
with MilliQ water purification system (Millipore, Molsheim, France). 
2.2. Biotinylation of human liver microsomes 
To enable immobilization of HLM on streptavidin-functionalized 
microreactor surfaces, the HLM were first biotinylated off-chip by 
spontaneous fusion between biotin-tagged fusogenic liposomes (b-FL) 
and the HLM, following a previously developed protocol (Kiiski et al., 
2019). The b-FL were prepared by mixing chloroform solutions of DOPE 
(10 mg/mL), DOTAP (10 mg/mL), biotin-cap-DOPE (10 mg/mL), and 
lissamine rhodamine B-DOPE (1 mg/mL) lipids in a mass ratio of 
1:1:0.1:0.05. After evaporating the solvent under nitrogen gas, the dry 
lipids were kept in vacuum for 2 h to remove any residual solvent before 
resolvating the dry lipid film in PBS buffer. This yielded large multi-
lamellar liposomes with a total lipid concentration of 2 mg/mL. To 
ensure complete solvation, the lipid dispersion was vortexed for 1 h at 
room temperature after which the large multilamellar liposomes were 
extruded through a porous polycarbonate membrane (pore size of 0.1 
µm) to yield large unilamellar vesicles (220 ± 25 nm, n=4 batches) with 
fusogenic properties, i.e., the b-FL. Finally, the b-FL (2 mg/mL lipid 
concentration in PBS) and the commercial HLM (20 mg/mL total protein 
in 250 mM sucrose) stock solutions were mixed in equal volumes and 
incubated at 37◦C for 15 min to yield the biotinylated HLM (b-HLM) 
solution with 10 mg/mL total protein concentration. 
2.3. Microreactor fabrication and biofunctionalization 
The microreactors were made of off-stoichiometric thiol-enes (OSTE) 
and incorporated a 30 × 4 × 0.2 mm (length × width × height) 
micropillar array featuring ca. 14 400 pillars (Ø 50 μm) in a hexagonal 
lattice with interpillar (center-to-center) distance of 100 µm and a total 
effective volume of ca. 18.3 µL (Fig. 1A and B). The manufacturing 
protocol consisted of four steps: (i) microfabrication of SU-8 masters of 
the micropillar and cover layers, (ii) soft lithography of the PDMS molds 
of the micropillar and cover layers with the assistance of the SU-8 
masters, (iii) UV replica molding of the micropillar and cover layers in 
OSTE with the assistance of the PDMS molds, and (iv) bonding of the 
OSTE micropillar and cover layers to obtain a sealed micropillar chan-
nel. The SU-8 master (step i) was fabricated by photolithography, similar 
to Kiiski et al. (2019). The PDMS molds (step ii) were prepared by 
mixing the Sylgard 184 base elastomer and the curing agent in a weight 
ratio of 10:1, degassing the mixture under vacuum for 30 min, and 
curing in the oven against the SU-8 masters (either at 80◦C for 3 h or 
65◦C overnight). The OSTE layers were prepared by mixing the tetra-
thiol and triallyl monomers in a ratio yielding 25% molar excess of thiol 
functional groups. The monomer mixture was then poured onto the 
PDMS mold, degassed under vacuum for ca. 5 min, and cured under UV 
for 5 min (Dymax 5000-EC Series UV flood exposure lamp, nominal 
power 225 mW/cm2, Dymax Corporation, Torrington, CT). After curing, 
the OSTE micropillar and cover layers were laminated against each 
other (step iv) and the bonding was finalized with an additional UV 
exposure through the cover layer for 2 min (Dymax 5000-EC). The 
structural fidelity of the OSTE-based micropillar arrays was examined by 
scanning electron microscopy (Quanta™ 250 FEG, FEI, Hillsboro, OR) 
using a platinum coating (ca. 5 nm coating thickness). 
Next, the microreactor surface was functionalized step-wise with 
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biotin and streptavidin before immobilization of the b-HLM (Fig. 1C). 
First, the thiol-rich microchannel was filled with biotin-PEG4-alkyne 
(0.1 mM in ethylene glycol, with 1% Irgacure® TPO-L) and exposed to 
UV through the cover layer for 1 min (λ = 365 nm, LED, nominal in-
tensity 14 mW/cm2) to initiate the reaction between the surface thiols 
and the alkyne. After this initial biotinylation step, the microchannel 
was rinsed sequentially with methanol and water (≥5 mL each). Then, 
the microchannel was coated with streptavidin (0.5 μg/mL in PBS) via 
incubation at room temperature (RT) for 30–45 min, and rinsing with 
≥5 mL PBS. Finally, the prebiotinylated HLM (b-HLM) was immobilized 
onto the micropillars by filling the streptavidin-coated microchannel 
with b-HLM solution (10 mg/mL, prepared as described above), and 
incubating at 4 ◦C overnight. To avoid evaporation of the b-HLM solu-
tion, the microchannel inlet and outlet were sealed with Parafilm®. 
Before use, the microreactor was rinsed with ≥5 mL of the incubation 
buffer to remove the excess (non-immobilized) b-HLM. The average 
amount of the immobilized b-HLM was equivalent to 0.021 ± 0.010 mg 
total microsomal protein (n=4 microreactors). The amount of the 
immobilized b-HLM was determined by measuring the total protein 
concentration of the rinse solution (after b-HLM immobilization) with 
the Pierce™ BCA Protein Assay Kit (Thermo Fischer Scientific, Rockford, 
IL) and comparing its protein concentration with that of the filling so-
lution (b-HLM, 10 mg/mL total protein). 
2.4. Microfluidic drug glucuronidation assays 
The UGT activity of immobilized HLM was determined by feeding 
the substrate (either 8-hydroxyquinoline (8-HQ) or zidovudine) and the 
cosubstrate (1 mM UDPGA), both dissolved in Tris buffer (0.1 M, 5 mM 
MgCl2, pH 7.5), through the reactor at a constant volumetric flow rate of 
5 µL/min. As the volume of the micropillar array was ca. 18.3 µL, this 
corresponds to a residence time of 3.7 min. The enzyme stability was 
determined using a constant concentration of the substrate (50 μM 8- 
HQ) and other reagents and an external syringe pump (one pump 
configuration). The impact of residence (reaction) time on the metabo-
lite yield was additionally determined between 1.2 min (15 µL/min) and 
7.3 min (2.5 µL/min) by adjusting the flow rate of the feed solution 
accordingly. For enzyme kinetic determinations (zidovudine glucur-
onidation), a two-pump configuration was used so that one pump line 
was feeding constant concentration of the substrate and the cosubstrate 
(6000 μM zidovudine, 1 mM UDPGA) and the other pump line only the 
cosubstrate (1 mM UDPGA). These two feed solutions were mixed off- 
chip, with the help of a three-way T-piece tubing connector, before 
introducing the combined flow to the microreactor. The two pump lines 
were programmed so that the total combined flow rate remained un-
changed (5 μL/min) during the experiment, but the relative share of the 
substrate solution varied from 1% (equivalent to 60 μM zidovudine) to 
100% (equivalent to 6000 μM zidovudine) of the total volumetric flow. 
All microreactor experiments were conducted at physiological tem-
perature (ca. 37◦C) by placing an aluminum heating element under the 
reactor (Fig. 1A). The heating power was adjusted automatically using a 
PID controller employing a thermocouple (both from Omega Engineer-
ing Inc., Stamford, CT) attached to the top of the microreactor cover 
layer and adjusted to 35 ◦C, assuming ca. 2 ◦C difference between the top 
surface and the inside temperature on the basis of the previous study 
(Sikanen et al., 2008). The impacts of alamethicin (50 μg/mL) or bovine 
serum albumin (0.1%, m/v) on UGT activity under flow-through con-
ditions were determined by adding these to the feed solution, where 
indicated. Additionally, the impact of alamethicin on the UGT activity 
was determined by preincubating the microreactor with alamethicin 
(500 µg/mL in Tris buffer) at 4◦C for 30 min before initiating the 
flow-through experiment. 
The amounts of the produced metabolites were quantitated by 
fluorescence (8-hydroxyquinoline glucuronide) or liquid 
chromatography-mass spectrometry (LC-MS, zidovudine glucuronide) 
from 50 µL fractions of the output solution collected using a refrigerated 
fraction collector (CMA 470, CMA Microdialysis AB, Solna, Sweden). For 
fluorescence analysis (ex/em 245/475 nm), the 50 μL fractions were 
diluted 1:1 with Tris buffer, acidified with 10 µL of 4 M HClO4, and 
analyzed with a Varioskan LUX well plate reader (Thermo Scientific, 
Vantaa Finland). For mass spectrometric (MS) analysis, the 50 μL frac-
tions were diluted 1:1 with acetonitrile and analyzed using an ACQUITY 
UPLC™ liquid chromatograph (Waters, Milford, MA) and Xevo TQ-S 
triple quadrupole mass spectrometer (Waters, Manchester, UK). The 
Fig. 1. Overview of the microreactor layout. A) 
A schematic top view of the microreactor with 
annotated dimensions and a schematic side 
view of the experimental setup. B) A scanning 
electron microscopy (SEM) detail of the micro-
pillar array and a photograph of the micro-
reactor. C) Schematic view of the enzyme 
immobilization and reactor functionalization 
protocols with a graphical illustration (insert on 
the right) of a typical UGT-mediated glucur-
onidation reaction occurring on the luminal 
side of the ER membrane.   
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LC-MS data were analyzed using MassLynx V4.1 software. The chro-
matographic and MS parameters and method validation results for 
zidovudine glucuronide quantitation are provided in the Supplementary 
material (Tables S1-S2 and Figure S1). The enzyme activities in flow- 
through conditions were calculated by dividing the metabolite concen-
tration of the outcome with the residence time (dependent on the flow 
rate) and the amount of the immobilized HLM (0.021 ± 0.010 mg total 
microsomal protein). To allow comparison with static incubations, these 
enzyme activities (µM/min/mg protein) were multiplied with the reac-
tion volume of the static enzyme incubations (100 µL) to balance the 
initial amount of the substrate and thus obtain same unit activities 
(pmol/min/mg protein). 
2.5. Determination of drug glucuronidation in static enzyme incubation 
conditions 
The control UGT activities in non-immobilized HLM were deter-
mined in sample tubes using a total volume of 100 µL, and a total protein 
concentration of 0.2 mg/mL (8-HQ incubations) or 0.1 mg/mL (zido-
vudine incubations) in Tris buffer (0.1 mM, 5 mM MgCl2, pH 7.5). Where 
indicated, the HLM preincubation with alamethicin (50 μg/mL) was first 
conducted at 4 ◦C for 30 min. The HLM and the substrate were further 
preincubated at 37◦C for 5 min before initiating the reaction by the 
addition of the cosubstrate (UDPGA, 1 mM). The substrate concentra-
tions were either 50 μM (8-HQ) or between 25 and 6400 μM (zidovu-
dine, enzyme kinetic determinations). After the desired incubation time 
(10 min for 8-HQ and 30 min for zidovudine), the reactions were 
terminated by the addition of 10 µL of 4 M HClO4, the solutions kept on 
ice for 20 min, and centrifuged at 16 000 g for 10 min to precipitate the 
enzymes. The supernatants were analyzed by fluorescence (8-HQ in-
cubations) or LC-MS (zidovudine incubations), similar to the fractions 
collected from the microreactors. The enzyme activities in static con-
ditions were calculated by dividing the metabolite amount produced 
(pmol) with the amount of HLM (mg total microsomal protein) and the 
reaction time. 
The impacts of the tetrathiol or triallyl monomers used in the 
microfabrication, and possibly leaching out of the bulk polymer, on the 
activity of 8-HQ glucuronidation were additionally examined in static 
conditions by adding either of the monomers to the incubation buffer at 
concentrations between 0.01 and 1000 µM (Supplementary material, 
Figure S2). 
2.6. Statistics 
All results are presented as mean ± standard deviation from repeated 
experiments, the number of which is indicated in the context of each 
dataset. Enzyme kinetic parameters were calculated by fitting the 
experimental data to the Michaelis-Menten equation. Statistical differ-
ence between kinetic parameters (KM, VMAX) were evaluated using the 
extra sum-of-squares F-test. Other statistical analyses were performed 
using the Student’s t-test using 95% confidence interval criteria, i.e., 
p<0.05 for statistically significant difference. All statistical analyses and 
curve fittings were performed using GraphPad Prism version 8.4.3 
(GraphPad Software, San Diego, CA). 
3. Results and discussion 
3.1. Impact of biotinylation and immobilization on the microsomal UGT 
activity 
Microreactor performance was initially characterized using 8- 
hydroxyquinoline, a substrate metabolized by several UGTs to yield a 
fluorescent metabolite, 8-hydroxyquinoline glucuronide, which can be 
selectively quantified by fluorescence (Smith, 1953). The HLM immo-
bilization approach exploited in this study is based on biotinylation of 
the microsomal membranes upon their spontaneous fusion with 
biotin-containing fusogenic liposomes. Since the functionalization 
method does not target the protein structure, but the surrounding lipid 
membrane, it is unlikely to affect the enzyme function similar to 
immobilization strategies based on covalent bonding between the pro-
tein and the solid support, which represent the majority of previous 
work (Sheldon, 2007). Furthermore, when the biotinylated HLM is 
immobilized on an avidin-coated micropillar array, the system is 
scaffold-free, and the HLM remains accessible to the UGT substrates and 
cosubstrate (UDPGA) so that the enzyme kinetic determinations are not 
impaired by the system-restricted mass transfer typically associated with 
scaffold-based systems (i.e., enzymes entrapped in porous matrices 
(Sheldon, 2007)). However, the fusion process inevitably results in al-
terations in the lipid composition of the microsomal membrane, which 
may have an impact on the diffusion of UGT substrates and cosubstrate 
to the luminal side of the membrane or result in conformation changes in 
the protein structure due to lipid-protein interactions. These are both 
critical processes affecting the kinetics of UGT-catalyzed reactions in 
vitro (Hochman et al., 1981; Palaiokostas et al., 2018; Vessey and 
Zakim, 1971). 
To examine the impact of the HLM biotinylation (fusion) process on 
the apparent UGT activity, we first determined the 8-HQ glucur-
onidation rate in native and biotinylated HLM under static conditions (in 
sample tubes) and compared the obtained activity with that of 
alamethicin-pretreated HLM (Fig. 2A and B). Preincubation of HLM with 
alamethicin, and the subsequent pore formation in the microsomal 
membrane, is currently considered the gold standard to overcome UGT 
latency, and typically preferred over the use of surfactants, which show 
much narrower concentration dependency (Fisher et al., 2000). In this 
study, a statistically significant (p = 0.02, Student’s t-test) increase in 
the UGT activity was observed in biotinylated HLM with approximately 
25% greater activity over native HLM in static conditions (Fig. 2B). The 
observed increase in the UGT activity may be explained, for instance, by 
the relative increase of long-chain fatty acids, which has been reported 
to elevate UGT activity (Hochman et al. 1981), or by the introduction of 
non-lamellar DOPE into the microsomal membrane, which has been 
reported to promote membrane permeation of small molecules (Pal-
aiokostas et al., 2018). The observed activity increase was, however, 
negligible compared with that achieved by alamethicin preincubation 
(Fig. 2B), suggesting that biotinylation does not result in a similar 
physical membrane disruption as alamethicin-induced pore formation. 
In static conditions, the synergistic impact of biotinylation (membrane 
fusion) and alamethicin preincubation (pore formation) was statistically 
insignificant compared with that of alamethicin alone (Fig. 2B). On this 
basis, it was concluded that although the biotinylation (fusion) process 
exploited in this study alters the membrane composition, it preserves the 
UGT activity somewhat close to that of the intact HLMs. Overall, these 
results are consistent with the ‘compartmentalization hypothesis’ (Liu 
and Coughtrie, 2017), which is the most widely accepted theory sug-
gesting that the UGT latency is best explained by the diffusion-limited, 
impaired mass transfer of the UGT substrates and cosubstrate through 
the microsomal membrane in vitro. In static conditions, the diffusion rate 
thus delimits the maximal reaction rate unless the diffusional re-
strictions are eliminated, for instance, with the help of alamethicin 
induced pore formation. 
When immobilized onto the microreactor surface, the UGT activity of 
b-HLM was shown to be highly stable over time, with a negligible 
decrease in enzyme activity within the first 10 h of continuous use, and a 
rather minor decrease during the subsequent 5 h period (Fig. 2C). The 
within-run variation (n=6 subsequent fractions, each 50 μL) determined 
for 8-HQ glucuronidation at a flow rate of 5 µL/min was between 0.7 and 
7.4% RSD (for n=4 individual microreactors) and the chip-to-chip 
variation of the average activities was 21.0% RSD. Further validation 
of the flow-through UGT assays confirmed that the UGT activity of the 
immobilized HLM was dependent on the reaction temperature, as ex-
pected, similar to that of non-immobilized native HLM in static condi-
tions (Figure 2D). Overall, these results confirmed that the membrane 
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biotinylation and subsequent immobilization of the b-HLM is a robust 
protocol and does not result in enzyme inactivation or leaching of the 
immobilized enzymes out of the microreactor along with the applied 
flow. It was also confirmed that neither of the monomers used in the 
fabrication of the microreactors resulted in any kind of enzyme inhibi-
tion up to at least 1 mM concentration (Supplementary material, 
Figure S2). Thus, the UGT activity was concluded unaffected by chem-
ical artifacts possibly originating from the microreactor manufacturing 
process. 
3.2. Impact of flow-through conditions on the determination of 
microsomal UGT activity 
In addition to enzyme stability, the mass transfer in flow-through 
conditions merits special attention. Upon diffusion of the reaction 
components across the immobilized HLM membrane, the flow-through 
system eventually reaches a steady state, resulting in a plateau level of 
UGT activity (Fig. 3A). In this study, the impact of alamethicin pore 
formation on the maximum achievable glucuronidation activity in flow- 
through conditions was examined using 8-HQ as the model substrate and 
two different approaches for alamethicin treatment, including (i) pre-
incubation of the microreactor with alamethicin (500 µg/mL in Tris 
buffer, 30 min, 4◦C) before initiation of the experiment and (ii) addition 
of alamethicin (50 µg/mL) to the feed solution during the experiment 
(Fig. 3A). At high flow rates (here, 15 µL/min corresponding to resi-
dence time of 1.2 min), similar increase in the absolute 8-HQ glucur-
onidation activity was observed with alamethicin, as in the case of static 
assays (Fig. 3A vs. 2B). Preincubation of the microreactor with alame-
thicin enabled elimination of diffusional restrictions and readily resulted 
in about two-fold greater UGT activity compared with the plateau level 
activity of microreactors not treated with alamethicin. By adding ala-
methicin to the feed solution, even a greater increase in the UGT activity 
(ca. three-fold) was achieved as soon as the steady-state was reached 
within about 15 min (Fig. 3A). However, in addition to alamethicin, the 
flow rate has huge impact on the steady-state formation under flow- 
through conditions, as it controls the residence time of the substrate 
within the system. Thus, the flow rate affects the equilibrium of the 
substrate concentration in the cytosolic and luminal sides of the 
immobilized HLM and its impact must also be accounted for when 
deriving enzyme kinetic constants from flow-through experiments. 
In this study, the impact of the residence time on the UGT activity 
was determined by quantitating the metabolite concentration from 50 
μL fractions of the feed solution, run through the microreactor and 
analyzed off-chip by fluorescence. This volume was considered the most 
feasible for further handling to ensure adequate sample manipulation 
accuracy. However, the time required for the fraction collection (à 50 
μL) is also proportional to the flow rate and varies between 3.3 min (15 
μL/min) and 20 min (2.5 μL/min) with the flow rates used in this study. 
In practice, this means that at the highest flow rate (15 µL/min), 3-4 
dummy fractions need to be collected before the steady state condi-
tion is reached (t=15 min and onward), as is illustrated with the help of 
8-HQ glucuronidation in Fig. 3A. At the lowest flow rate (2.5 μL/min), 
the fraction collection takes 20 min and already the second fraction is 
thus representative of the UGT activity of the steady state. However, 
comparison of the fraction-specific activities at different flow rates, in 
the absence of (Fig. 3B) and with alamethicin in feed solution (Fig. 3C), 
revealed that, as the residence time of the substrate increased (i.e., the 
flow rate decreased), the accelerating impact of alamethicin became 
negligible. Further comparison of the amounts of metabolite produced 
per fraction, at conditions representative of the steady-state at each flow 
rate, confirmed that the reaction was not diffusion-limited as the amount 
metabolite increased linearly as a function of residence time in both 
cases (Fig. 3D). However, in the absence of alamethicin, the metabolite 
production rate (pmol per residence time) was somewhat higher 
compared with that of alamethicin-treated microreactors, and reached 
saturation at residence times t>3-4 min (Fig. 3D). Assuming maximum 
UGT activity of about 4 µM/min (Fig. 3B), the residence times beyond 4 
min yield >16 µM metabolite concentrations, which correspond to 
>32% conversion of the substrate (50 µM 8-HQ) to its respective 
metabolite. Thus, the results suggest that the flow-through reaction 
obeys Michaelis-Menten type kinetics, in which excessive substrate 
depletion results in concentration-dependent first-order kinetics and 
thus, reduced reaction velocity. Instead, with alamethicin in feed, the 
metabolite amount increased linearly over residence time at all flow 
rates tested, only at a somewhat lower rate (pmol per residence time) 
compared with microreactors not treated with alamethicin (Fig. 3D). 
The apparent difference in the alamethicin impact between the static 
assays (Fig. 2B) and the flow-through microreactor assays (Fig. 3D) may 
Fig. 2. Characterization of the UGT enzyme 
activity and stability. A) A schematic visuali-
zation of the effects of (i) alamethicin and (ii) 
liposome fusion on the membrane structure and 
permeability of human liver microsomes. B) 
The effect of alamethicin (ala) on the 8-HQ 
glucuronidation rate in non-immobilized 
native HLM and biotinylated HLM (b-HLM) 
when the enzyme incubation is conducted in 
sample tubes (à 100 μL) in static conditions. 
The error bars represent the variation between 
n=3 individual incubations. C) The stability of 
the UGT activities of two parallel microreactors 
featuring immobilized HLM over a 15-hour- 
long experiment at a flow rate of 2.5 µL/min. 
Activity presented as % of maximal activity of 
each microreactor. D) The effect of temperature 
on UGT activity under static (soluble HLM, n=3 
incubations each) and flow-through conditions 
(n=4 microreactors, 2.5 µL/min). 8-hydroxy-
quinoline was used as the probe substrate at a 
concentration of 50 µM in all experiments.*p- 
value < 0.05, **p-value < 0.005 (Student’s t- 
test). n.s. = not significant.   
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be explained by the inherent differences in the quantitation of the 
metabolite amount between static and flow-through experiments. The 
results derived from static assays always represent the cumulative 
amount of the produced metabolite over the entire reaction time, and 
thus, in the absence of alamethicin, they reflect the average of the initial 
and steady-state reaction velocities. Instead, the flow-through assays are 
capable of revealing the transient activity so that the steady-state ve-
locity can be distinguished from the initial velocity, as illustrated in 
Fig. 3A. Thus, on the basis of the microreactor experiments, it may be 
concluded that if only the residence time of the substrate is long enough 
to reach equilibrium between the cytosolic and luminal concentrations, 
the enzymatic reaction proceeds with constant velocity, so that the 
amount of the metabolite produced is dependent on the reaction time, 
but independent of alamethicin (pores). Furthermore, our results further 
hint at even somewhat greater UGT activity in the absence of alame-
thicin (Fig. 3D). Explaining the exact mechanism of this finding would 
warrant further studies beyond the scope of this paper, but it may be 
hypothesized that the artificial alamethicin pore in the HLM membrane 
shifts the equilibrium of the enzyme-substrate complex formation 
(E+S⇌ES) toward the reverse dissociation. As a result, the concentra-
tion of the ES complex in the lumen may decrease and result in reduced 
metabolite formation rate (ES→E+M) compared with the situation in 
intact microsomes. To be able to compare these reaction velocities with 
those of the static assays, the maximum steady-state 8-HQ glucur-
onidation activities measured on microreactors (in µM/min, Figs. 3B and 
C) were divided by the amount of the immobilized HLM (0.021±0.010 
Fig. 3. The alamethicin effect on UGT activity 
of immobilized HLM in flow-through condi-
tions. A) The impact of alamethicin on the 
steady-state formation time in a microreactor 
operated at a flow rate of 15 uL/min. Data point 
frequency is one every 3.3 min for collection of 
50 μL fractions. The error bars represent the 
deviation between n=4 microreactors in each 
case. B-C) UGT activity in subsequent fractions 
1–3 (each 50 uL) collected from the micro-
reactor at different flow rates in the absence (B) 
and presence of alamethicin (C). The error bars 
represent the deviation between n=4 (without 
alamethicin) and n=4 (with alamethicin) 
microreactors. D) The impact of residence time 
on the amount of 8-HQ-glucuronide produced 
per fraction on microreactors in the absence of 
alamethicin and with alamethicin included in 
the feed solution (50 µg/mL). The error bars 
represent the deviation between n=4 micro-
reactors in each case.   
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mg total protein) and multiplied with the reaction volume of the static 
assays (100 µL) so as to equalize the initial amount of the substrate. The 
so obtained activities were 1.95±0.42 × 104 pmol/min/mg protein in 
the absence of alamethicin and 1.58±0.49 × 104 pmol/min/mg protein 
with alamethicin in feed, both determined at a flow rate of 7.5 µL/min 
(n=4 microreactors each). These values correlated well with the 8-HQ 
glucuronidation activity in the static assays with alamethicin 
(2.31±0.03 × 104 pmol/min/mg protein, n=3 incubations) and were 
substantially greater than those measured in the static conditions in the 
absence of alamethicin (Fig. 2B). 
Overall, these observations are consistent with the compartmental-
ization hypothesis, according to which the apparent increase in reaction 
velocity observed in the presence of alamethicin in static endpoint as-
says is not due to intrinsic changes in UGT activity but the elimination of 
mass transfer barriers. However, in flow-through conditions, the steady- 
state velocity can be distinguished from the initial (diffusion-limited) 
velocity and thus the use of alamethicin does not confer any substantial 
advantages. As the use of alamethicin on microreactors also resulted in a 
slightly higher chip-to-chip variation (Figs. 3B-C), it was excluded from 
all subsequent enzyme kinetic experiments. 
3.3. Determination of in vitro intrinsic clearances under flow-through 
conditions 
Enzyme inhibition caused by free fatty acids released from artificial 
microsomal preparations, that affect both CYPs and UGTs alike (Pal-
acharla et al., 2017; Rowland et al., 2007), is an alternative theory to 
explaining the underestimation of drug clearance in isolated microsomal 
preparations in vitro. Typically, elimination of the fatty acid artifacts is 
achieved by adding albumin to the in vitro enzyme incubations. A 
well-known target of fatty acid-induced inhibition is UGT2B7, which is 
responsible for the glucuronidation of ca. one-third of marketed drugs 
(Williams et al., 2004), making it one of the clinically most important 
UGT enzymes. Zidovudine is a specific UGT2B7 substrate, whose in vivo 
clearance is significantly underestimated based on in vitro data (Boase 
and Miners, 2002) unless albumin is added to the in vitro enzyme 
incubations. To further evaluate the feasibility of the flow-through 
microreactor technology for predicting the in vivo clearance of thera-
peutic drugs, we determined the enzyme kinetic parameters (KM and 
VMAX) of zidovudine in the presence and absence of albumin. Although 
albumin may also change the free unbound concentration of the test 
substrate, binding of zidovudine to albumin is negligible and the albu-
min effect has been associated with sequestering of the free fatty acids, 
which eventually results in a substantial increase in the in vitro intrinsic 
clearance of zidovudine (Manevski et al., 2011; Rowland et al., 2007). 
This effect was also examined in our own experiments with and without 
alamethicin in static conditions (Fig. 4A) as well as on microreactors not 
treated with alamethicin (Fig. 4B). To examine the impact of albumin on 
the zidovudine glucuronidation kinetics in flow-through conditions, we 
used an interconnected two-pump configuration, which enabled the 
creation of a concentration gradient covering ca. two orders of magni-
tude (60–6000 μM zidovudine). At each zidovudine concentration, three 
subsequent fractions, each 50 μL, were collected at a flow rate of 5 
µL/min (residence time of 3.7 min). Despite the considerable difference 
in the partition coefficients between zidovudine (logP ≈ 2) and 8-HQ 
(logP ≈ 0.05), the time required for steady-state formation and reach-
ing the equilibrium between the cytosolic and luminal substrate con-
centrations was comparable in both cases (Supplementary material, 
Figure S3). Thus, to ensure that the system had reached the steady state, 
the kinetic constants were determined using the glucuronide amount of 
the last of the three fractions collected at each zidovudine concentration. 
On the basis of the microreactor characterization conducted with the 
help of 8-HQ glucuronidation, alamethicin was excluded from the 
flow-through microreactor experiments with zidovudine. 
In the absence of albumin, the enzyme affinity (KM) of zidovudine 
glucuronidation in static assays increased upon addition of alamethicin, 
whereas the KM derived from microreactor experiments was between 
these two values (Fig. 4C). However, the maximal activity (VMAX) 
derived from microreactor experiments was somewhat larger compared 
with that of static assays conducted with and without alamethicin 
(Fig. 4D), which resulted in a statistically similar intrinsic clearance 
(CLint) as that of the static assays conducted with alamethicin (Fig. 4E). 
Fig. 4. Comparison of zidovudine glucur-
onidation kinetics in static and flow-through 
conditions. Michaelis-Menten kinetics deter-
mined for zidovudine glucuronidation using A) 
static, endpoint incubations, and B) micro-
reactors not treated with alamethicin. In static 
assays, the samples were assayed in duplicate 
with and without bovine serum albumin (BSA, 
0.1 % w/v) and/or alamethicin (ala, 50 μg/mL). 
For the microreactors, the error bars represent 
the deviation between n=3 microreactors for 
which the zidovudine glucuronidation rate was 
determined with and without BSA (0.1 % w/v) 
by quantitating the metabolite from the third 
fraction (à 50 μL) collected at each concentra-
tion. The zidovudine concentration gradient 
was created by feeding 6000 μM zidovudine in 
the incubation matrix (0.1 M Tris, 5 mM MgCl2, 
1 mM UDPGA) from one syringe and the blank 
incubation matrix from another syringe and 
mixing these appropriately by adjusting the 
ratio of the two flows while maintaining a total 
flow rate of 5 μL/min (3.7 min residence time) 
over the entire duration of the experiment. 
Summaries of C) the enzyme affinities, D) 
maximal enzyme activities, and E) intrinsic 
clearances obtained for zidovudine glucur-
onidation in static and flow-through conditions. 
*p-value < 0.05, **p-value < 0.005, ***p-value 
< 0.0005 (Student’s t-test). n.s. = not 
significant.   
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Supplementing the enzyme incubations with purified bovine serum al-
bumin resulted in a clear decrease in the KM values derived from both 
static and microreactor experiments (Fig. 4C), but it did not much 
impact the VMAX values (Fig. 4D). In static conditions, the VMAX was 
mostly impacted by alamethicin preincubation, whereas the VMAX 
values derived from microreactor experiments were statistically similar 
with and without albumin (Fig. 4D). As expected based on previous 
literature, the combined impact of alamethicin and albumin in static 
conditions resulted in approximately 11-fold increase in the intrinsic 
clearance (VMAX/KM) of zidovudine, from 24±2 nL/min/mg protein in 
intact HLM to 268±17 nL/min/mg protein with alamethicin and albu-
min (Fig. 4E). The intrinsic clearance derived from microreactor ex-
periments, supplemented with albumin, was 390±100 nL/min/mg 
protein and thus statistically similar with that of the static assays con-
ducted in the presence of both albumin and alamethicin (Fig. 4E). As the 
flow effectively removes any soluble fatty acid artifacts from the cytosol 
side of the immobilized microsomal membrane, these results suggest 
that the inhibitory fatty acid artifacts are likely accumulated on the 
luminal side as well, and albumin helps sequester the fatty acids upon 
their partitioning across the microsomal membrane. These results also 
suggest that conducting drug glucuronidation assays under flow- 
through conditions could likely improve the in vitro-in vivo extrapola-
tion of drug clearance compared with intact microsomes, without 
needing to use artificial membrane-disruptive agents such as 
alamethicin. 
4. Conclusions 
A microfluidic reactor incorporating immobilized human liver mi-
crosomes was introduced to the study of UGT-mediated drug meta-
bolism under flow-through conditions. The microreactor was 
characterized with respect to key performance parameters, including 
temperature-dependency and long-term stability. The decrease in 
enzyme activity within the first 10 h of continuous use at 37 ◦C was less 
than 20%. We also confirmed that the materials used in the microreactor 
fabrication did not interfere with UGT metabolism. In addition, the 
governing principles for the determination of enzyme kinetic parameters 
under flow-through conditions were drawn to examine UGT metabolism 
in general and to shed light on the latency associated with UGT assays in 
vitro via alamethicin and albumin effects. In flow-through conditions, 
alamethicin was shown to have a negligible impact on the drug clear-
ance, whereas the albumin effect (fatty acid sequestering) was similarly 
reproduced in flow-through and static conditions. As a result, the ki-
netics of zidovudine glucuronidation (the model reaction used in this 
study) under flow-through conditions was in good agreement with that 
obtained using microsomal incubations supplemented with alamethicin 
and albumin. Considering the possibility to re-use a single microreactor 
continuously for at least 10 h without significant loss of UGT activity, 
the theoretical maximum number of samples (à 50 μL) collected, for 
example, at a flow rate of 5 μL/min (à 10 min per aliquot), is as high as 
sixty. This suffices for, e.g., determination of the enzyme kinetic pa-
rameters of two-three drug compounds per a single microreactor, 
assuming that minimum of three representative aliquots are collected at 
six or more different drug concentrations for each compound. Further-
more, our results suggest that conducting drug glucuronidation assays 
under flow-through conditions may shed light on the mechanism-based 
UGT studies by enabling new designs of experiments not feasible for 
static enzyme incubations, such as time-resolved studies of enzyme 
function and creation of time-dependent concentration gradients of the 
substrates, cosubstrates or inhibitors. 
CRediT authorship contribution statement 
Iiro Kiiski: Conceptualization, Methodology, Investigation, Valida-
tion, Formal analysis, Writing - original draft. Elisa Ollikainen: Meth-
odology, Writing - review & editing. Sanna Artes: Investigation. Päivi 
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